July 20, 2016 8:52am

First customer orders, ONVO is UP +$0.14 or +3.63% to $4.00

 


 

ONVO is on track to commercialize its second tissue, the kidney proximal tubule, in Q3/16.

As part of its pre-commercialization activities, Organovo introduced an early access program for preferred partners and has signed the first customer orders to study the effects of drug exposure on the kidney proximal tubule.

 

The Bottom Line: initial customers are using the kidney model to study key aspects of kidney pharmacology, including compound transport, metabolism and toxicity.

ONVO closed at $3.86 and is UP +$0.14 to $4.00